Who are Immuneering Corporation's main suppliers?

Immuneering Corporation (IMRX) key suppliers include: AVENTIS, Eli Lilly and Company, Eli Lilly and Company, REGENERON-PHARMACEUTICALS, SANOFI and 3 more. View the full supplier network at chainsifter.com/chain/IMRX.

Who are Immuneering Corporation's major customers?

Immuneering Corporation (IMRX) key customers include: Sanofi, Sanofi, LEERINK-PARTNERS-LLC, Q-EMERGING-GROWTH-COMPANY. View the full customer network at chainsifter.com/chain/IMRX.

What sector is Immuneering Corporation in?

Immuneering Corporation (IMRX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Immuneering Corporation Supplier List (IMRX): 8 Verified Suppliers

8Suppliers

4Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Immuneering Corporation (IMRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships

2Distinct source URLs

12High confidence

0.843Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Immuneering Corporation Suppliers

Ticker	Name	Confidence	Evidence
AVENTIS	AVENTIS	92%	The Company entered into the September 2025 Purchase Agreement with Aventis, a wholly-owned subsidiary of Sanofi, pursuant to which the Company agreed to sell securities to Aventis in the September 2…
LLY	Eli Lilly and Company	92%	In August 2025, we announced a clinical supply agreement with Eli Lilly and Company for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982), which intends to support the evaluation of a…
LLY	Eli Lilly and Company	92%	Reciprocal relationship from LLY graph: Reciprocal relationship from IMRX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMRX graph: In August 2025, we announced a clinic…
REGENERON-PHARMACEUTICALS	REGENERON-PHARMACEUTICALS	92%	In February 2025, we announced entry into a clinical supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 therapy, Libtayo® (cemiplimab), which intends to support the evaluation of atebi…
SANOFI	SANOFI	92%	The Company entered into the September 2025 Purchase Agreement with Aventis, a wholly-owned subsidiary of Sanofi, pursuant to which the Company agreed to sell securities to Aventis in the September 2…
PIPER-SANDLER-CO	PIPER-SANDLER-CO	90%	On August 10, 2022, the Company entered into an Equity Distribution Agreement (the "2022 Sales Agreement") with Piper Sandler & Co (the "Sales Agent"), to sell shares of its common stock with aggrega…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	85%	On September 26, 2025, we completed the September 2025 Offering, pursuant to which we issued and sold 18,959,914 shares of our common stock at an offering price of $9.23 per share, with Leerink Partn…
OPPENHEIMER-CO-INC	OPPENHEIMER-CO-INC	85%	On September 26, 2025, we completed the September 2025 Offering, pursuant to which we issued and sold 18,959,914 shares of our common stock at an offering price of $9.23 per share, with Leerink Partn…

Immuneering Corporation Customers

Ticker	Name	Confidence	Evidence
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMRX graph: Reciprocal relationship from SNYN…
SNYNF	Sanofi	72%	urces of Liquidity We finance our operations through the issuance of convertible notes payable, convertible preferred stock, common stock, warrants exercisable for common stock, and the exercise of s…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	62%	urces of Liquidity We finance our operations through the issuance of convertible notes payable, convertible preferred stock, common stock, warrants exercisable for common stock, and the exercise of s…
Q-EMERGING-GROWTH-COMPANY	Q-EMERGING-GROWTH-COMPANY	62%	urces of Liquidity We finance our operations through the issuance of convertible notes payable, convertible preferred stock, common stock, warrants exercisable for common stock, and the exercise of s…

Immuneering Corporation Debt Obligations

Instrument	Description	Confidence	Evidence
IMRX-DEBT-10250	Warrants outstanding: 308308	90%	xbrl warrant detail from xbrl 2021-12-31.
IMRX-DEBT	Debt stack $3.7M	90%	Market cache reports total debt of $3.7M.
IMRX-DEBT-10251	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.

Immuneering Corporation Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Immuneering Corporation.

Immuneering Corporation Ownership

Holder	Name	Confidence	Evidence
IMRX-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 95 tracked holders.

Immuneering Corporation Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
CTMX	CytomX Therapeutics, Inc.	100.00	2
GRDX	GridAI Technologies Corp.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
ATOS	Atossa Therapeutics, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2

Immuneering Corporation Supply Chain